NCT03940534

Utilization of the TAD Device for Dispensing Pain Medications in Hospice Patients

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Intent Solutions, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A novel device, TAD, has been developed to aid adherence to prescribed regimens and may have a roll in hospice pain management. This study aims to assess medication adherence relating to missed doses or improperly timed doses with and without the aid of a mobile device as a primary endpoint. Secondary endpoints will be patient, nursing, and provider satisfaction.

Detailed description

This study is a randomized crossover study in which patients will be randomized to start with or without a mobile device assisting the patient or caregiver in using the device. The investigators aim to enroll 20 patients across 3 sites. Each patient is expected to participate in the study for 12 weeks. After the first 2 weeks of participation, the patient will either begin using the mobile device to assist or will stop using the mobile device for the next 2 weeks. after the initial 4 weeks, the patient will choose to continue with or without using the mobile device.

Conditions

• Medication Adherence
• Satisfaction, Personal

Interventions

Type	Name	Description
DEVICE	TAD	TAD is a device used to aid medication adherence.

Timeline

• Start date: 2018-03-09
• Primary completion: 2019-02-26
• Completion: 2019-02-26
• First posted: 2019-05-07
• Last updated: 2019-05-08

Locations

3 sites across 1 country: United States

Regulatory

• FDA-regulated device study